“What's so great about the ArteraAI platform is the simplicity in which this test is performed,” says Rana R. McKay, MD.
In this video, Rana R. McKay, MD, discusses the benefits of ArteraAI in prostate cancer. McKay is a medical oncologist and associate professor of medicine at the University of California, San Diego.
AI-based tools really have broad utility and broad utilization in cancer care. They can be utilized to help with cancer detection, they can be utilized to help with prognostication, they can be utilized as predictive biomarkers potentially to guide therapy decisions. And so I think there's very broad application across the spectrum from diagnosis to treatment.
What are the benefits of the ArteraAI Prostate Test?
What's so great about the ArteraAI platform is the simplicity in which this test is performed. Basically utilizing digitalized pathology slides, the algorithm identifies a risk score that can be important for prognostication and can also be important for response to ADT. And so all that's needed for the test is either digitalized images of the H&E slides, or if those can't be digitalized, then just submission of 2 to 3 H&E images. There's no wasting of tissue or wasting of specimens. There's nothing that's actually extracted off of the slide. The images get digitalized. And then the algorithm is applied on to those images to basically help identify the risk of recurrence and also ADT response. That's basically the main utility is that it's prognostic and potentially predictive of ADT response.
This transcript was edited for clarity.